- Home
- TIL
TIL
Instil Bio Inc.
as 06-17-2025 4:00pm EST
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | DALLAS |
| Market Cap: | 230.1M | IPO Year: | 2021 |
| Target Price: | $119.00 | AVG Volume (30 days): | 518.4K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -11.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.62 - $92.00 | Next Earning Date: | 08-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Instil Bio Inc. News
TIL Breaking Stock News: Dive into TIL Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet
GlobeNewswire
6 days ago
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
Zacks
13 days ago
Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice
GlobeNewswire
15 days ago
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer
GlobeNewswire
18 days ago
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference
Zacks
19 days ago
Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?
Zacks
19 days ago
Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade
GlobeNewswire
25 days ago
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
Compare TIL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TIL Instil Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.